Schroder Investment Management Group’s Seres Therapeutics MCRB Stock Holding History

Schroder Investment Management Group’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,922	Closed	-$2.35M	–	1534
2021 Q2	$2.35M	Buy	4,922 +172	+4%	+$72.6K	﹤0.01%	983
2021 Q1	$1.96M	Buy	4,750 +221	+5%	+$102K	﹤0.01%	1020
2020 Q4	$2.22M	Sell	4,529 -1,238	-21%	-$725K	﹤0.01%	977
2020 Q3	$3.19M	Buy	5,767 +415	+8%	+$138K	0.01%	810
2020 Q2	$509K	Buy	5,352 +919	+21%	+$80.6K	﹤0.01%	1003
2020 Q1	$294K	Hold	4,433	–	–	﹤0.01%	1054
2019 Q4	$306K	Hold	4,433	–	–	﹤0.01%	1115
2019 Q3	$348K	Hold	4,433	–	–	﹤0.01%	1104
2019 Q2	$285K	Sell	4,433 -4,940	-53%	-$469K	﹤0.01%	1051
2019 Q1	$1.29M	Buy	9,373 +2,129	+29%	+$260K	﹤0.01%	856
2018 Q4	$655	Buy	7,244 +486	+7%	+$68K	﹤0.01%	958
2018 Q3	$1.03M	Hold	6,758	–	–	﹤0.01%	937
2018 Q2	$1.24M	Buy	6,758 +3,460	+105%	+$565K	﹤0.01%	893
2018 Q1	$484K	Hold	3,298	–	–	﹤0.01%	1062
2017 Q4	$669K	Hold	3,298	–	–	﹤0.01%	1053
2017 Q3	$1.09M	Buy	+3,298	New	+$901K	﹤0.01%	965

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schroder Investment Management Group's MCRB Position: Q3 2021 in Review

Schroder Investment Management Group sold out of Seres Therapeutics (MCRB) in Q3 2021, closing a stake of 4,922 shares — an estimated $2.35M sold.

Schroder Investment Management Group first reported a position in MCRB in Q3 2017 and held it in 16 quarters. The position peaked at $3.19M in Q3 2020. 133 funds tracked by Wall St. Rank hold MCRB as of Q3 2021.

Schroder Investment Management Group reported no remaining Seres Therapeutics position as of Q3 2021 after selling out during the quarter.
Schroder Investment Management Group sold 4,922 Seres Therapeutics shares in Q3 2021, an estimated $2.35M.
Schroder Investment Management Group first reported a position in Seres Therapeutics in Q3 2017 and held it in 16 quarters.
Schroder Investment Management Group's Seres Therapeutics position peaked at $3.19M in Q3 2020.
133 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2021.

Based on Schroder Investment Management Group's 13F filing for Q3 2021, filed 12 Nov 2021.